FDA Drug Recalls

Recalls / Class II

Class IID-0283-2019

Product

Clopidogrel Tablets, USP, 300 mg, 30 (5 x 6 unit-dose) count blister pack, Rx only, Manufactured by Dr. Reddy's Laboratories Limited, Srikakulam - 532 409, India, NDC 55111-671-31

Brand name
Clopidogrel Bisulfate
Generic name
Clopidogrel Bisulfate
Active ingredient
Clopidogrel Bisulfate
Route
Oral
NDC
55111-671
FDA application
ANDA091023
Affected lot / code info
Lot #: T600530, Exp 11/18

Why it was recalled

Failed Dissolution Specification: Out-of-Specification results were observed for dissolution at 18th month stability testing.

Recalling firm

Firm
Dr. Reddy's Laboratories, Inc.
Manufacturer
Dr.Reddy's Laboratories Limited
Notification channel
Letter
Type
Voluntary: Firm initiated
Address
107 College Rd E, N/A, Princeton, New Jersey 08540-6623

Distribution

Quantity
4,212 (30-count blister pack)
Distribution pattern
U.S.A.nationwide

Timeline

Recall initiated
2018-11-07
FDA classified
2018-11-27
Posted by FDA
2018-11-28
Terminated
2020-05-19
Status
Terminated

Source: openFDA Drug Enforcement endpoint. Recall record D-0283-2019. The FDA issues recall classifications as health-hazard assessments, not legal findings; for legal claims consult a licensed attorney.

Class II recall: Clopidogrel Bisulfate · FDA Drug Recalls